Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
11.94
+0.98 (8.94%)
At close: Sep 17, 2026, 4:00 PM EDT
11.97
+0.03 (0.25%)
After-hours: Sep 17, 2026, 7:59 PM EDT
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Faheem Hasnain |
Contact Details
Address: 3115 Merryfield Row, Suite 120 San Diego, California 92121 United States | |
| Phone | 858 684 1300 |
| Website | gossamerbio.com |
Stock Details
| Ticker Symbol | GOSS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001728117 |
| CUSIP Number | 38341P201 |
| ISIN Number | US38341P2011 |
| Employer ID | 47-5461709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President and Chairman |
| Bryan Giraudo | Chief Operating Officer and Chief Financial Officer |
| Robert Paul Smith Jr. | Chief Commercial Officer |
| Christian Waage J.D. | Executive Vice President, General Counsel and Secretary |
| Jeanine Anthony | Senior Vice President of Marketing |
| Deanna Weber | Executive Vice President of Human Resources |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Caryn L. Peterson | Chief Development Officer |
| Kelly Dawson | Senior Vice President and Program Team Lead |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 8-K | Current Report |
| Sep 9, 2026 | 8-K | Current Report |
| Sep 4, 2026 | D | Notice of Exempt Offering of Securities |
| Sep 3, 2026 | PRE 14A | Other preliminary proxy statements |
| Sep 3, 2026 | 8-K | Current Report |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 24, 2026 | SCHEDULE 13D/A | Filing |
| Aug 21, 2026 | 8-K | Current Report |